Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
New Drug Briakinumab May Be the Answer for Psoriasis | |
|
| |
Briakinumab
holds promise to be an effective drug
for improving psoriasis. This experimental drug was demonstrated to be far more
effective than methotrexate, the commonly used drug for the skin condition. Psoriasis is a chronic skin
condition that produces red, dry plaques of thickened skin. The recent
trial comparing the use of briakinumab with methotrexate in psoriasis was
published in the October 27 issue of the New England Journal of Medicine. Critics opine that with the
advent of the new drug, the word 'remission' is now on the table.
Briakinumab is a genetically engineered protein developed by Abbott Laboratories for the treatment of a number of conditions like psoriasis, rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis. The drug was found to effect a dramatic improvement in 60 percent of psoriasis patients who used it. Skin lesions produced by psoriasis cleared up in about three times as many patients who got briakinumab as those who got methotrexate.
Methotrexate has been the mainstay of treatment of psoriasis for decades. The new experimental drug belongs to a group of drugs called biologics, i.e. drugs created by biologic processes, rather than being chemically synthesized. Biologics have easier-to-use risk profiles and are much safer than methotrexate.
Psoriasis is an autoimmune disease that is yet to have a complete cure. It can however be controlled with medications. Tremendous research has produced a number of promising therapies for the condition. Study researcher Kristian Reich, MD says that "This drug (Briakinumab) has had, in this trial, the highest efficacy we have ever seen with any biologic in psoriasis before."
The current trial weighed the effects of briakinumab against the classical therapy with methotrexate. A total of 317 patients with moderate to severe psoriasis took part in the study. About 60 percent of the 154 patients treated with briakinumab showed near or complete clearance of skin lesions produced by psoriasis. This result could be achieved only by about 10% to 20% of 163 patients in the group of patients taking methotrexate.
The drug does come with serious side effects, like a higher risk of certain forms of cancer like breast cancer and prostate cancer. Herpes Zoster infection was another serious adverse effect observed. The side effects of briakinumab were not significantly different from those in patients treated with methotrexate.
On account of the side effects and the requirement of clearer scrutiny, the drug is yet to be completely approved for patients. There has also been criticism of the trial blaming it for 'being too short and including too few patients to detect harm'.
Reference: N Engl J Med. 2011;365:1586-1596.
Source-Medindia
| |
|
|
More News on: Drug Toxicity, Clinical Trials - Different Phases of the trial , Signature Drug Toxicity, Psoriasis, Pruritus, Drugs Banned in India
 Comment & Contribute
|
Related Links
Psoriasis
Psoriasis is a recurrent and complex inflammatory skin disorder that can have tremendous physical and psychological impact on the ...
Generalized pustular psoriasis
This is one of the most severe forms of psoriasis. The precipitating factors are intermittent infections, hypocalcemia and sudden withdrawal of ...
Alcohol Exacerbates Skin Diseases and Psoriasis
Alcohol can damage skin causing rosacea, porphyria cutanea tarda, post-adolescent acne, discoid eczema and psoriasis. ...
Health Watch News
Stroke Survivors Need Emotional Support
Stroke is a condition characterized by death of brain cells due to inadequate supply of oxygen to brain cells. It can be of two types-hemorrhagic ...
Red Hair Pigment May Increase Risk of Melanoma, Skin Cancer
Fair skin is associated with increased risk of skin cancer. However, recent animal studies reveal that factors other than UV radiations are ...
Depression can be Treated by Deep Brain Stimulation
Deep Brain Stimulation may be used to treat depression, reveal new studies. Deep Brain Stimulation is a technique in which a ...
How Much Vitamin D is Needed for Infants?
We all know very well that vitamin D or 'the sunshine vitamin' is required for the growth and development of healthy bones. In the initial ...
You Will Invite Hatred by Fat Talk
You might be conscious about being overweight but make a point to avoid talking about your obesity with others, as nobody likes it or is interested ...
Dual Parenting More Beneficial Than Single Parenting, Shows Brain Research
Canadian research suggests that dual parenting may be more beneficial than single parenting. It may offer the advantage of enhancing brain cell ...
- Health News Index
 | Quiz on Psoriasis Psoriasis is an autoimmune skin disease occurring in almost all parts of the body and affecting people of all ages. 
|
- News Quick Links
 | News Central | | Health Watch | |
| Latest Health News | | Health In Focus | |
| News Category (500+) | | Breaking Health News | |
| Popular News | | Celebrating Life | |
| Health News and Press Release | | Medindia - Exclusive | |
| News Photo Gallery | | India Special | |
| News Video Gallery | | Lifestyle and Wellness | |
| News From Other Resources | |||
 |
Psoriasis
Complete Medindia Resources
|
| News Categories: |
| » | US Teens Share More Online, But Protect Their Privacy: Survey |
| » | Gay Ministers Voted In By Church of Scotland |
| » | Unilever: Dove 'Sketches' Most-watched Online Ad |
| » | Controversial Ads on Teen Pregnancy Show Heavily Pregnant Boys |
| » | New Waterproof Fabric That Drains Sweat |
| More Life Style News | |
|
Ask an Expert
